The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Treatment of Patients With EBV-Positive Relapsed Hodgkin's Disease
Abstract
Adoptive transfer of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs) is effective prophylaxis and treatment of EBV-positive immunoblastic lymphoma in immunocompromised patients. In 50% of patients with Hodgkin's disease, the tumor cells are EBV antigen-positive and may therefore also be suitable targets for treatment with virus-specific CTLs. However, Hodgkin's disease may produce several inhibitory effects on immune induction and effector function in vivo, which may preclude the generation or effector function of CTLs reactive against EBV viral proteins, including those expressed by the tumor cells. We have investigated whether EBV-specific CTLs could be generated ex vivo from 13 patients with Hodgkin's disease: nine with active relapsed disease and four who were in clinical remission after a first or subsequent relapse. CTL lines were successfully generated from nine of 13 patients (five active disease, four remission). Although these lines had an abnormal pattern of expansion comparable to EBV-specific CTLs generated from normal donors, their phenotype was normal except for reduced expression of the zeta chain of the T-cell receptor (TCR). Their cytotoxicity was also compared to EBV-specific lines generated from normal donors and included activity against LMP2a, one of the three weakly immunogenic viral antigens expressed by Hodgkin's tumor cells. To assess the activity of the CTLs in vivo, they were gene-marked and infused into three patients with multiply relapsed disease. The CTLs persisted for more than 13 weeks postinfusion and retained their potent antiviral effects in vivo, thereby enhancing the patient immune response to EBV. This approach may therefore have value in the treatment of EBV-positive Hodgkin's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rooney, C. M., Ng, C. Y. C., Loftin, S., Smith, C. A., Li, C., Krance, R. A., Brenner, M. K., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91150-2 · Cited by 1,173
Self-citationRelease of Infectious Epstein-Barr Virus by Transformed Marmoset Leukocytes
Miller, G., & Lipman, M. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.1.190 · Cited by 941
Strand, S., Hofmann, W. J., Hug, H., Müller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., & Galle, P. R. (1996) · Nature Medicine · doi:10.1038/nm1296-1361 · Cited by 897
Detection of Epstein–Barr Viral Genomes in Reed–Sternberg Cells of Hodgkin's Disease
Weiss, L. M., Movahed, L. A., Warnke, R. A., & Sklar, J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200806 · Cited by 886
Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald-Mullen, P. M., Klein, G., Kurilla, M. G., & Masucci, M. G. (1995) · Nature · doi:10.1038/375685a0 · Cited by 823
Heslop, H. E., Ng, C. Y. C., Li, C., Smith, C. A., Loftin, S. K., Krance, R. A., Brenner, M. K., & Rooney, C. M. (1996) · Nature Medicine · doi:10.1038/nm0596-551 · Cited by 821
Self-citationEpstein-Barr virus in AIDS-related primary central nervous system lymphoma
MacMahon, E., Charache, P., Glass, D., Mann, R. B., Becker, P. S., Hayward, D., McArthur, J., & Ambinder, R. F. (1991) · The Lancet · doi:10.1016/0140-6736(91)91837-k · Cited by 518
Complex Complexes: Signaling at the TCR
Wange, R. L., & Samelson, L. E. (1996) · Immunity · doi:10.1016/s1074-7613(00)80315-5 · Cited by 511
Murray, R. J., Kurilla, M. G., Brooks, J. M., Thomas, W. A., Rowe, M., Kieff, E., & Rickinson, A. B. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.1.157 · Cited by 499
Khanna, R., Burrows, S. R., Kurilla, M. G., Jacob, C. A., Misko, I. S., Sculley, T. B., Kieff, E., & Moss, D. J. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.1.169 · Cited by 384
Cited by
Epstein–Barr virus: 40 years on
Young, L. S., & Rickinson, A. B. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1452 · Cited by 2,227
Cohen, J. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430707 · Cited by 1,636
Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533
Self-citationDoubrovina, E., Oflaz-Sozmen, B., Prockop, S. E., Kernan, N. A., Abramson, S., Teruya-Feldstein, J., Hedvat, C., Chou, J. F., Heller, G., Barker, J. N., et al. (2012) · Blood · doi:10.1182/blood-2011-08-371971 · Cited by 421
Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease
Bollard, C. M., Aguilar, L., Straathof, K. C., Gahn, B., Huls, M. H., Rousseau, A., Sixbey, J., Gresik, M. V., Carrum, G., Hudson, M., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040890 · Cited by 388
Self-citation
Metadata
- Authors
- Roskrow, M. A., Suzuki, N., Gan, Y.-J., Sixbey, J. W., Ng, C. Y. C., Kimbrough, S., Hudson, M., Brenner, M. K., Heslop, H. E., & Rooney, C. M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1998-04-15
- Volume
- 91
- Issue
- 8
- Pages
- 2925-2934
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W151068973
- Cited by
- 283
- References
- 20
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Treatment of Patients With EBV-Positive Relapsed Hodgkin's Disease. https://app.cochat.ai/papers/10.1182/blood.v91.8.2925.2925_2925_2934
- The paper
- Roskrow, M. A., Suzuki, N., Gan, Y.-J., Sixbey, J. W., Ng, C. Y. C., Kimbrough, S., Hudson, M., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (1998). Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Treatment of Patients With EBV-Positive Relapsed Hodgkin's Disease. Blood. https://doi.org/10.1182/blood.v91.8.2925.2925_2925_2934
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.